Remission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection

Simple item page
dc.contributor.authorEmsley R.
dc.contributor.authorOosthuizen P.
dc.contributor.authorKoen L.
dc.contributor.authorNiehaus D.J.H.
dc.contributor.authorMedori R.
dc.contributor.authorRabinowitz J.
dc.date.accessioned2011-05-15T15:59:17Z
dc.date.available2011-05-15T15:59:17Z
dc.date.issued2008
dc.description.abstractRecently proposed criteria for remission by a 'Remission in Schizophrenia Working Group' have generated considerable interest. We assessed rates, predictors, and correlates of remission in a sample of patients with first-episode schizophrenia treated with injectable, long-acting risperidone. This allowed us to examine remission among patients known to be receiving medication. This was a single-site open-label study in which 50 newly diagnosed cases of schizophreniform disorder or schizophrenia aged 16 to 43 years were treated with injectable, long-acting risperidone 25-50 mg every 2 weeks for 2 years. Remission, according to Remission in Schizophrenia Working Group criteria, was achieved in 64% of the patients. Of those achieving remission, 97% maintained this status until study completion. Remission was associated with greater improvements in other symptom domains, insight, and social and occupational functioning. Patients in remission received lower doses of antipsychotic medication, had fewer extrapyramidal symptoms, and a more favorable attitude toward medication. The results of this open-label study suggest that a majority of first-episode patients who receive long-acting injectable antipsychotic medication may achieve sustained remission. Double-blind-controlled studies using long-acting injectable antipsychotics in early psychosis are warranted to further test this. © 2008 Wolters Kluwer Health | Lippincott Williams & Wilkins.
dc.description.versionArticle
dc.identifier.citationInternational Clinical Psychopharmacology
dc.identifier.citation23
dc.identifier.citation6
dc.identifier.issn2681315
dc.identifier.other10.1097/YIC.0b013e32830c2042
dc.identifier.urihttp://hdl.handle.net/10019.1/11095
dc.subjectbiperiden
dc.subjectfluoxetine
dc.subjectlorazepam
dc.subjectorphenadrine
dc.subjectpropranolol
dc.subjectrisperidone
dc.subjectadolescent
dc.subjectadult
dc.subjectakathisia
dc.subjectarticle
dc.subjectclinical article
dc.subjectclinical trial
dc.subjectdepression
dc.subjectdrug dose increase
dc.subjectdrug formulation
dc.subjectdrug withdrawal
dc.subjectextrapyramidal symptom
dc.subjectfemale
dc.subjecthuman
dc.subjectmale
dc.subjectpatient compliance
dc.subjectpriority journal
dc.subjectquality of life
dc.subjectremission
dc.subjectschizophrenia
dc.subjectschizophreniform disorder
dc.subjecttreatment response
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAntipsychotic Agents
dc.subjectDelayed-Action Preparations
dc.subjectDrug Administration Schedule
dc.subjectFemale
dc.subjectHumans
dc.subjectInjections
dc.subjectMale
dc.subjectProspective Studies
dc.subjectRemission Induction
dc.subjectRisperidone
dc.subjectSchizophrenia
dc.subjectSchizophrenic Psychology
dc.subjectTreatment Outcome
dc.subjectYoung Adult
dc.titleRemission in patients with first-episode schizophrenia receiving assured antipsychotic medication: A study with risperidone long-acting injection
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Publications